Comparison of the effects of placebo, ranitidine, famotidine and nizatidine on intragastric acidity by means of continuous pH recording
- PMID: 2568299
- DOI: 10.1159/000199818
Comparison of the effects of placebo, ranitidine, famotidine and nizatidine on intragastric acidity by means of continuous pH recording
Abstract
The effects of single daily doses of placebo, nizatidine 300 mg, ranitidine 300 mg and famotidine 40 mg, given at 22.00 h, have been compared in 16 patients with healed duodenal ulcers. Each of them underwent the above treatment on four separate occasions. The three H2 receptor antagonists showed a significantly higher acid inhibition than placebo (p less than 0.003) throughout the whole 24-hour period. Famotidine turned out to be more effective than nizatidine (p less than 0.02) in reducing circadian acidity, while there was no difference between ranitidine and nizatidine. The effects of the three H2 blockers on overnight acidity (from 23.00 to 07.00) were similar to each other, whereas both famotidine (p less than 0.003) and ranitidine (p less than 0.02) produced more anacidity than nizatidine during the morning hours (from 07.00 to 12.00). The time period elapsed in consecutive minutes above 5.0 pH units during drug-related events was significantly longer with both famotidine (p less than 0.01) and ranitidine (p less than 0.01) compared to nizatidine. Therefore in the recommended dosages for clinical use the acid suppression of nizatidine was significantly shorter-lasting than that of both ranitidine and famotidine. The major change is represented by the lack of carryover effect of nizatidine on morning acidity.
Similar articles
-
Continuous intragastric pH monitoring: a real progress in the assessment of antisecretory drugs.Ital J Gastroenterol. 1990;22 Suppl 2:20-3. Ital J Gastroenterol. 1990. PMID: 1983412 Clinical Trial.
-
[Inhibition of 24-hour acidity by nizatidine].Fortschr Med. 1989 May 10;107(14):321-4. Fortschr Med. 1989. PMID: 2568971 Clinical Trial. German.
-
Twenty-four-hour control of gastric acidity by twice-daily doses of placebo, nizatidine 150 mg, nizatidine 300 mg, and ranitidine 300 mg.J Clin Pharmacol. 1993 Jan;33(1):70-4. doi: 10.1002/j.1552-4604.1993.tb03906.x. J Clin Pharmacol. 1993. PMID: 8429117 Clinical Trial.
-
Clinical review of histamine2 receptor antagonists.Arch Intern Med. 1990 Apr;150(4):745-51. Arch Intern Med. 1990. PMID: 1970232 Review.
-
Comparison of famotidine with cimetidine and ranitidine.Clin Pharm. 1988 Apr;7(4):271-84. Clin Pharm. 1988. PMID: 2896559 Review.
Cited by
-
Histamine H2-receptor antagonists in peptic ulcer disease. Efficacy in healing peptic ulcers.Drugs. 1992 Nov;44(5):709-19. doi: 10.2165/00003495-199244050-00003. Drugs. 1992. PMID: 1280563 Review.
-
Variability in individual response to various doses of omeprazole. Implications for antiulcer therapy.Dig Dis Sci. 1994 Jan;39(1):161-8. doi: 10.1007/BF02090077. Dig Dis Sci. 1994. PMID: 8281852 Clinical Trial.
-
Nizatidine versus placebo in gastroesophageal reflux disease. A six-week, multicenter, randomized, double-blind comparison. Nizatidine Gastroesophageal Reflux Disease Study Group.Dig Dis Sci. 1992 Jun;37(6):865-74. doi: 10.1007/BF01300384. Dig Dis Sci. 1992. PMID: 1587191 Clinical Trial.
-
Case Study of a Refractory Idiopathic Peptic Ulcer in Which 24-h Intragastric pH Monitoring Contributed to Its Pathophysiological Analysis.Case Rep Gastroenterol. 2024 Jul 31;18(1):386-394. doi: 10.1159/000540185. eCollection 2024 Jan-Dec. Case Rep Gastroenterol. 2024. PMID: 39144819 Free PMC article.
-
Helicobacter pylori and luminal gastric pH. Relationships in nonulcer dyspepsia.Dig Dis Sci. 1992 Mar;37(3):378-84. doi: 10.1007/BF01307731. Dig Dis Sci. 1992. PMID: 1735361
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources